• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital.降钙素原在 COVID-19 患者抗生素管理中的应用:一家地区综合医院的质量改进项目。
Clin Med (Lond). 2021 Jan;21(1):e71-e76. doi: 10.7861/clinmed.2020-0614. Epub 2020 Dec 18.
2
Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia.抗生素管理:基于降钙素原水平的 COVID-19 肺炎抗生素的早期停药。
J Clin Pharm Ther. 2022 Feb;47(2):243-247. doi: 10.1111/jcpt.13554. Epub 2021 Nov 11.
3
Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study).在 COVID-19 大流行的第一波期间,为 NHS 急性医院中患有 COVID-19 肺炎的患者制定抗生素处方决策模型:降钙素评估 COVID-19 住院患者抗生素使用情况(PEACH 研究)的定性结果。
BMJ Open. 2023 Dec 19;13(12):e077117. doi: 10.1136/bmjopen-2023-077117.
4
The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.降钙素原指导 COVID-19 住院患者使用抗生素的成本效益:PEACH 研究的一部分。
J Antimicrob Chemother. 2024 Aug 1;79(8):1831-1842. doi: 10.1093/jac/dkae167.
5
Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels.住院 COVID-19 患者降钙素原的特征及降钙素原水平分层的抗生素使用的临床结局。
Intern Emerg Med. 2022 Aug;17(5):1405-1412. doi: 10.1007/s11739-022-02955-5. Epub 2022 Mar 11.
6
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.C 反应蛋白和降钙素原在 COVID-19 中的抗菌药物管理作用。
Infection. 2021 Oct;49(5):935-943. doi: 10.1007/s15010-021-01615-8. Epub 2021 May 22.
7
Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19.降钙素原在 COVID-19 住院癌症患者中的抗菌药物管理作用。
Elife. 2022 Dec 21;11:e81151. doi: 10.7554/eLife.81151.
8
Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study).降钙素原指导下的抗生素治疗在普通急诊患者发热中的应用:一项多中心非劣效性随机临床试验(HiTEMP 研究)。
Clin Microbiol Infect. 2018 Dec;24(12):1282-1289. doi: 10.1016/j.cmi.2018.05.011. Epub 2018 Jun 2.
9
Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit.降钙素原作为重症监护病房中新冠肺炎患者抗生素管理工具的应用
J Glob Antimicrob Resist. 2020 Sep;22:782-784. doi: 10.1016/j.jgar.2020.07.017. Epub 2020 Jul 25.
10
Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19.降钙素原在抗生素个体化治疗中的应用:更新及在 COVID-19 中的重点关注。
Crit Rev Clin Lab Sci. 2022 Jan;59(1):54-65. doi: 10.1080/10408363.2021.1975637. Epub 2021 Sep 13.

引用本文的文献

1
Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources.降钙素原用于指导英格兰和威尔士医院第一波新冠疫情期间的抗生素使用:定量和定性来源研究结果的整合与三角互证
BMJ Open. 2025 Aug 8;15(8):e093210. doi: 10.1136/bmjopen-2024-093210.
2
Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review.C反应蛋白和降钙素原对COVID-19患者进行抗菌药物管理而言安全且有用吗?一项范围综述。
Antimicrob Steward Healthc Epidemiol. 2024 Sep 12;4(1):e129. doi: 10.1017/ash.2024.372. eCollection 2024.
3
A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19.回顾性倾向评分匹配队列研究:降钙素原检测对 COVID-19 第一波期间住院患者抗生素使用的影响。
J Antimicrob Chemother. 2024 Nov 4;79(11):2792-2800. doi: 10.1093/jac/dkae246.
4
The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.降钙素原指导 COVID-19 住院患者使用抗生素的成本效益:PEACH 研究的一部分。
J Antimicrob Chemother. 2024 Aug 1;79(8):1831-1842. doi: 10.1093/jac/dkae167.
5
Procalcitonin Levels in Identifying Bacterial Infections in Children with and without COVID-19.降钙素原水平在识别患和未患COVID-19儿童细菌感染中的作用
Infect Dis Clin Microbiol. 2023 Dec 29;5(4):287-291. doi: 10.36519/idcm.2023.300. eCollection 2023 Dec.
6
Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world.COVID-19 患者的细菌感染:降钙素原检测对现实世界中抗生素处方的影响。
BMC Infect Dis. 2024 Jan 19;24(1):106. doi: 10.1186/s12879-023-08849-x.
7
Antibiotic Usage in the COVID-19 Intensive Care Unit of an Infectious Diseases Hospital from Nord-Eastern Romania.罗马尼亚东北部传染病医院 COVID-19 重症监护病房的抗生素使用情况。
Medicina (Kaunas). 2023 Mar 24;59(4):645. doi: 10.3390/medicina59040645.
8
Procalcitonin Values Fail to Track the Presence of Secondary Bacterial Infections in COVID-19 ICU Patients.降钙素原水平无法追踪COVID-19重症监护病房患者继发性细菌感染的存在情况。
Antibiotics (Basel). 2023 Apr 5;12(4):709. doi: 10.3390/antibiotics12040709.
9
Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study.新冠肺炎住院患者抗生素使用的降钙素原评估(PEACH):一项回顾性观察研究方案
Methods Protoc. 2022 Nov 28;5(6):95. doi: 10.3390/mps5060095.
10
Procalcitonin as a Tool to Antimicrobial Stewardship in COVID-19 Patients with Superimposed Bacterial Infections: A Systematic Review.降钙素原作为COVID-19合并细菌感染患者抗菌药物管理的工具:一项系统评价
J Inflamm Res. 2022 Nov 3;15:6055-6064. doi: 10.2147/JIR.S377644. eCollection 2022.

本文引用的文献

1
Tackling antimicrobial resistance in the COVID-19 pandemic.应对新冠疫情中的抗菌药物耐药性问题。
Bull World Health Organ. 2020 Jul 1;98(7):442-442A. doi: 10.2471/BLT.20.268573.
2
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.COVID-19 住院患者的细菌和真菌感染:英国二级保健机构中的回顾性队列研究。
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
3
Co-infections in people with COVID-19: a systematic review and meta-analysis.COVID-19 患者合并感染:系统评价和荟萃分析。
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
4
How covid-19 is accelerating the threat of antimicrobial resistance.新冠病毒如何加速抗微生物药物耐药性的威胁。
BMJ. 2020 May 18;369:m1983. doi: 10.1136/bmj.m1983.
5
COVID-19: don't neglect antimicrobial stewardship principles!2019冠状病毒病:勿忽视抗菌药物管理原则!
Clin Microbiol Infect. 2020 Jul;26(7):808-810. doi: 10.1016/j.cmi.2020.04.024. Epub 2020 Apr 30.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Using Procalcitonin to Guide Antibiotic Therapy.使用降钙素原指导抗生素治疗。
Open Forum Infect Dis. 2016 Dec 7;4(1):ofw249. doi: 10.1093/ofid/ofw249. eCollection 2017 Winter.
8
Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis.降钙素原指导慢性阻塞性肺疾病急性加重期抗生素使用的荟萃分析
Eur Respir Rev. 2017 Jan 31;26(143). doi: 10.1183/16000617.0073-2016. Print 2017 Jan.
9
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.抗菌药物耐药性:抗生素过度使用相关风险及解决措施。
Ther Adv Drug Saf. 2014 Dec;5(6):229-41. doi: 10.1177/2042098614554919.
10
Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis.降钙素原作为脓毒症的诊断标志物:系统评价和荟萃分析。
Lancet Infect Dis. 2013 May;13(5):426-35. doi: 10.1016/S1473-3099(12)70323-7. Epub 2013 Feb 1.

降钙素原在 COVID-19 患者抗生素管理中的应用:一家地区综合医院的质量改进项目。

Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital.

机构信息

Chesterfield Royal Hospital, Chesterfield, UK.

University of Sheffield, Sheffield, UK, UK.

出版信息

Clin Med (Lond). 2021 Jan;21(1):e71-e76. doi: 10.7861/clinmed.2020-0614. Epub 2020 Dec 18.

DOI:10.7861/clinmed.2020-0614
PMID:33355197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7850181/
Abstract

Antibiotic stewardship during the COVID-19 pandemic is an important part of a comprehensive strategy to improve patient outcomes and reduce long-term adverse effects secondary to rising antibiotic resistance. This report describes a quality improvement project which incorporates the use of procalcitonin (PCT) testing to rationalise antibiotic prescribing in patients with suspected or confirmed COVID-19 at Chesterfield Royal Hospital. Data were collected from 118 patients with a total of 127 PCT levels checked over a period of 20 days. Each PCT level was correlated with the subsequent antibiotic outcome as well as the result of the COVID-19 PCR swab. Results indicate that antibiotics were either never started or were stopped within 48 hours in 72% of COVID-confirmed cases with a PCT less than 0.25 μg/L. Our findings suggest that procalcitonin testing, when used in combination with thorough clinical assessment, is a safe, simple and sustainable way of reducing antibiotic use in COVID-19.

摘要

在 COVID-19 大流行期间,抗生素管理是改善患者预后和减少因抗生素耐药性上升而导致的长期不良影响的综合策略的重要组成部分。本报告描述了一个质量改进项目,该项目结合了降钙素原 (PCT) 检测,以合理使用抗生素治疗切斯特菲尔德皇家医院疑似或确诊 COVID-19 的患者。在 20 天的时间里,从 118 名患者中收集了总共 127 次 PCT 水平检查的数据。每个 PCT 水平都与随后的抗生素结果以及 COVID-19 PCR 拭子的结果相关。结果表明,在 PCT 水平低于 0.25μg/L 的 COVID-19 确诊病例中,72%的患者的抗生素从未开始使用或在 48 小时内停止使用。我们的研究结果表明,降钙素原检测与彻底的临床评估相结合,是一种安全、简单且可持续的减少 COVID-19 中抗生素使用的方法。